Want to see AU:IMU full AI Analyst Report?
IMU Stock Chart & Stats
AU$0.07
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.07
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.46
Previous CloseN/A
Volume4.23M
Average Volume (3M)2.14M
Market Cap
AU$35.18M
Enterprise ValueAU$43.81
Total Cash (Recent Filing)AU$2.63M
Total Debt (Recent Filing)AU$6.30M
Price to Earnings (P/E)―
Beta2.27
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding533,088,260
10 Day Avg. Volume2,182,088
30 Day Avg. Volume2,137,260
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Relatively Low LeverageModest debt reduces immediate solvency pressure and leaves more flexibility than a highly leveraged structure. However, this benefit is tempered by shrinking assets and equity, so it does not remove the company’s need for future funding.
Immuno-Oncology PipelineA pipeline spanning multiple immunotherapy approaches provides potential long-term value creation if candidates demonstrate clinical efficacy. The focus on cancer biology also places the company in a structurally important therapeutic area, although development risk remains high.
Clinical Development FocusConcentrating resources on progressing drug candidates can build future strategic or partnering optionality rather than relying on a single marketed product. This remains a durable source of potential upside, but no commercial-scale revenue is currently established.
Bears Say
Persistent Losses And Zero RevenueThe absence of recurring product revenue and continuing sizable losses indicate that the business is not self-sustaining. Until a candidate is commercialized or monetized, operating costs will continue to depend heavily on external capital.
Structural Cash BurnPersistent cash consumption limits financial resilience and increases the frequency and importance of future fundraising. For a clinical-stage biotech, prolonged negative cash flow can constrain trial execution and raise dilution risk.
Weakening Equity BaseDeclining equity and assets suggest ongoing capital erosion from operating losses and cash burn. A smaller balance-sheet cushion reduces protection against setbacks and makes the company more vulnerable if funding conditions or investor support weaken.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.07 and its highest was AU$0.46 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$35.18M.
When is Imugene’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Imugene’s earnings last quarter?
Currently, no data Available
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imugene have?
Imugene has 533,088,260 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:IMU Sentiment 54%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$90.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-70.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Imugene
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―